As filed with the U.S. Securities and Exchange Commission on October 28, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the ...

Core Insights - Clearmind Medicine Inc. is participating in a webinar focused on women in psychedelic leadership, highlighting its commitment to advancing psychedelic medicine [1][2] - The CEO, Dr. Adi Zuloff-Shani, will share insights on the company's strategic direction and the broader psychedelic landscape [2][3] Company Overview - Clearmind is a clinical-stage biotech company dedicated to developing novel neuroplastogen-derived therapeutics for under-treated health issues, including alcohol use disorder, cocaine addiction, and obesity [1][4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents as needed [5] Event Details - The webinar titled "Women in Psychedelic Leadership: Driving Innovation & Governance" is scheduled for October 29, 2025, at 9:00 AM PT/noon ET, and will be accessible online [1][2][3] - Registration for the event is available through Eventbrite, inviting investors, researchers, and stakeholders to participate [3]

Core Insights - Clearmind Medicine Inc. has appointed Mary-Elizabeth Gifford as Chief of Global Impact to enhance US partnerships and regulatory advocacy in the psychedelic medicine sector [1][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogens-derived therapeutics to address under-treated health issues, including alcohol use disorder [4] - The company holds an intellectual property portfolio consisting of 19 patent families with 31 granted patents and aims to expand this portfolio opportunistically [5] Leadership and Expertise - Mary-Elizabeth Gifford previously served as Chief of Global Impact at Psyence BioMed and has extensive experience in psychedelic policies and regulatory landscapes [2][3] - Gifford has been recognized as a significant figure in the psychedelic industry, being named a "Psychedelic Titan" and described as "the most quietly influential woman working in psychedelics today" [3] Strategic Initiatives - Gifford's role will focus on bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines [1][3] - Clearmind is conducting clinical trials at prestigious institutions such as Yale School of Medicine and Johns Hopkins University, aiming to set industry standards for scientific rigor [3]

Core Insights - Atai Life Sciences is focused on transforming mental health care through next-generation psychedelic therapies, including VLS-01 for treatment-resistant depression and EMP-01 for social anxiety [1][2] - The company has a market capitalization of $1.3 billion and is looking to acquire Beckley Psytech to enhance its capabilities in psychedelic medicine [2] - Recent market activity shows strong investor confidence, with ATAI stock experiencing significant gains and a bullish outlook from analysts [3][7] Company Overview - Atai Life Sciences is a clinical-stage biotech based in Berlin and the Netherlands, specializing in psychedelic compounds and digital therapeutics for mental health disorders [2] - The company has a robust pipeline of therapies aimed at addressing unmet needs in mental health, particularly for conditions like depression and anxiety [5][6] Financial Performance - In Q2 2025, Atai reported revenue of $719,000, a 163% year-over-year increase, while net loss per share improved to $0.14 [10] - R&D expenses decreased to $11.1 million, reflecting cost management efforts, while general and administrative expenses rose to $14.9 million due to strategic initiatives [11] - Cash reserves increased to $95.9 million, bolstered by equity issuances and asset sales, positioning the company well for future growth [12] Market Activity - ATAI shares have surged 411% over the past 52 weeks, with a notable increase of 338% in 2025 and 281% over the last six months [7] - The stock reached an all-time high of $6.75 on October 20, 2025, indicating strong market interest and trading volume [8] Regulatory and Policy Developments - North Carolina is emerging as a leader in psychedelic therapy access, with bipartisan support for policy changes aimed at expanding treatment options [4][15] - A proposed Psychedelic Medicine Task Force and a $5 million research grant program are in the works to study the therapeutic potential of psychedelics [16] Analyst Expectations - Needham initiated coverage on ATAI stock with a "Buy" rating and a price target of $12, citing significant upside potential in its psychedelic pipeline [18] - Analysts project that Atai's lead candidate, BPL-003, could capture 20% of the market, potentially exceeding $2.5 billion in sales by 2035 [19] - The overall analyst sentiment is positive, with eight out of ten analysts recommending a "Strong Buy" rating for ATAI stock [19]

Core Points - Mydecine Innovations Group Inc. announced the results of its annual general and special meeting of shareholders held on October 1, 2025, where all resolutions were approved [1][2] Debt Settlements with Related Parties - Disinterested shareholders approved the settlement of debts totaling USD $1,386,391 owed to two insiders through the issuance of convertible debentures amounting to USD $100,000 [3] - A debt settlement agreement with CEO Josh Bartch was approved to settle CAD $1,309,836 of unpaid management fees, with a convertible debenture issued for the same amount [4] - The company settled CAD $7,878,792 owed to Pioneer Garage Limited through a convertible debenture with the same terms as the Bartch agreement [5] - The Settlement Debentures will not accrue interest prior to an event of default, with an interest rate of 8% per annum upon default [6] Debt Settlement with an Arm's Length Party - A debt settlement agreement was made with an arm's length creditor to settle CAD $243,479 of legal fees through a secured convertible debenture of USD $100,000, bearing 1% monthly interest [9][10] Share Consolidation - Shareholders approved a special resolution allowing the Board to consolidate the company's issued and outstanding common shares on a basis of up to one post-consolidation share for every 50 pre-consolidation shares [13]

Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies for unmet mental health needs [5] - It is the first life sciences biotechnology company specializing in psychedelic-based therapeutics to be listed on Nasdaq [5] - The company aims to address unmet mental health needs, particularly in palliative care, through an evidence-based approach [5] Upcoming Events - Psyence BioMed will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8–10, 2025 [1][9] - Dr. Neil Maresky, CEO of Psyence BioMed, will discuss the company's business strategy and pipeline during the conference [2] - A webinar for investors and shareholders is scheduled for September 16, 2025, featuring members of the Scientific Advisory Board [4] Strategic Positioning - The company emphasizes its unique operational footprint in Africa and commitment to clinical excellence as key differentiators in the psychedelic medicine sector [3] - Psyence BioMed aims to engage with global investors to highlight its differentiated approach in the industry [3]

Core Insights - PharmaTher Holdings Ltd. aims to become a global leader in ketamine-based pharmaceuticals, with a clear strategy for regulatory approval and international expansion [1][3] Regulatory Milestones - The FDA has set an approval goal date of August 9, 2025, which is a significant milestone for the company, potentially unlocking a multi-billion-dollar market opportunity [3][7] - The current global market for ketamine is valued at $750 million and is projected to grow at a CAGR of 16.4%, reaching approximately $3.42 billion by 2034 [3] Financial Position - The company is fully funded for all planned operations leading up to the FDA approval goal date and the initial U.S. commercial launch of its ketamine product [5][7] - PharmaTher has no plans for new equity or debt financing before the FDA approval date, indicating confidence in its current financial position [6][7] Commercial Strategy - The manufacturing of the ketamine product is based in the U.S., ensuring supply chain security and quality control [7][8] - PharmaTher is preparing for international regulatory submissions in Europe, the UK, Canada, Japan, and the APAC regions, expected to begin in the second half of 2025 [7][8] Expansion and Innovation - The company is exploring new therapeutic applications for ketamine, inspired by bipartisan support for psychedelic-assisted therapies [9] - PharmaTher aims to broaden its clinical pipeline, focusing on indications such as Parkinson's disease, ALS, and CRPS, as well as novel delivery systems [7][9] Leadership Vision - The CEO emphasizes the upcoming FDA approval goal date as a critical starting point for global expansion and new therapeutic indications [10]

Psychedelic Medicine - Psychedelic medicine 行业关注 psilocybin（一种迷幻蘑菇中的活性成分）的潜力，这得益于最近的一项研究 [1] - Ibogaine（一种从非洲灌木 Iboga 中提取的物质）也被 Psychedelic medicine 行业关注，因为各州正在努力批准相关药物 [1]

Core Insights - The field of psychedelic medicine is emerging, attracting investor interest due to its potential for growth and innovation [1] - Compass Pathways experienced a 13% increase in share price following the announcement of a completed step in its clinical trial [1] Company Developments - Compass Pathways has completed dosing in a late-stage clinical trial for its psilocybin treatment, COMP005 [2] - The phase 3 trial involves 258 patients with moderate to severe depression who have not responded to at least two prior treatments, with dosing conducted at 32 sites in the U.S. [3][4] - The company is expected to publish six-week primary endpoint results by the end of June [3] Industry Context - The CEO of Compass Pathways emphasized the milestone as critical in addressing the unmet need in treatment-resistant depression, highlighting the legitimacy of psychedelics as potential therapies for serious psychological disorders [5]